4,901 trials
Mild Cognitive Impairment · Alzheimer's Disease · Traumatic Brain Injury
Primary: Memory Test Accuracy on Trained Stimuli — 53.9; 37.6; 48.9; 37.3 Percent correct
Dengue Fever
Primary: Number of Participants With Solicited Local (Injection Site) Reactions Following Either Vaccine Administration (Day 0 or Day 90) by Maximum Severity as Assessed by the…
Chronic Obstructive Pulmonary Disease
Primary: Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests…
Healthy Volunteer Study
Primary: Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability. — 0; 4; 5; 1 subjects affected
Healthy
Primary: AUC (0-168); AUC (0-336); AUC (0-672); AUC (0-∞ ) of Interferon (IFN) Beta-1a — 36682; 87085; 279477; 176866 (pg/ml)*hour
Multiple Myeloma
Primary: Assessment of Safety of recMAGE-A3 + AS15 — 13; 8; 4; 0 participants
Chronic Kidney Disease · Hyperparathyroidism, Secondary · Secondary Hyperparathyroidism
Primary: Number of Participants With Adverse Events — 3; 0; 0; 0 participants
Breast Cancer
Primary: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Trastuzumab — 1610; 1800; 1350; 2500 days•μg/mL
Malignant Melanoma, Neoplasms
Primary: Area Under the Plasma Concentration Time-curve From Zero to the Last Measurable Concentration Time Point (AUClast) of Vemurafenib — 125; 76.7 mcg*h/mL
Alpha 1-Antitrypsin Deficiency
Primary: Adverse Events Possibly, Probably or Definitely Related to Study Drug — 2; 2; 3; 2 participants
Hereditary Tyrosinemia, Type I
Primary: Maximum Observed Plasma Concentration (Cmax) — 1168.23; 1054.32 ng/mL
Influenza · Healthy
Primary: Solicted Adverse Events — 8; 12; 13; 14 participants
Healthy
Primary: Baseline Corrected Area Under the Concentration-Time Curve From Zero to Last Quantifiable Concentration (AUC 0-t,Adj) for Follicle-Stimulating Hormone (FSH) — 3187.4…
Hereditary Tyrosinemia, Type I
Primary: Maximum Observed Plasma Concentration (Cmax) — 1137.40; 1080.69; 1168.71 ng/mL
Myelodysplastic Syndrome
Primary: Adverse Events — 1 participants